Wall Street brokerages expect that Waters Co. (NYSE:WAT – Get Rating) will report sales of $632.87 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Waters’ earnings. The highest sales estimate is $635.00 million and the lowest is $629.60 million. Waters reported sales of $608.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4%. The firm is expected to report its next earnings report before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Waters will report full-year sales of $2.92 billion for the current year, with estimates ranging from $2.91 billion to $2.94 billion. For the next fiscal year, analysts anticipate that the company will post sales of $3.08 billion, with estimates ranging from $3.06 billion to $3.10 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Waters.
Waters (NYSE:WAT – Get Rating) last posted its quarterly earnings data on Tuesday, February 1st. The medical instruments supplier reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.47 by $0.20. Waters had a net margin of 24.87% and a return on equity of 239.12%. The firm had revenue of $836.00 million during the quarter, compared to analysts’ expectations of $820.40 million. During the same quarter in the previous year, the company posted $3.65 EPS. Waters’s revenue was up 6.2% on a year-over-year basis.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NuWave Investment Management LLC bought a new stake in Waters in the 1st quarter valued at $111,000. Nordea Investment Management AB lifted its position in Waters by 16.6% during the 1st quarter. Nordea Investment Management AB now owns 349,084 shares of the medical instruments supplier’s stock worth $112,213,000 after buying an additional 49,600 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Waters by 0.9% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 4,556 shares of the medical instruments supplier’s stock worth $1,414,000 after buying an additional 40 shares in the last quarter. DNB Asset Management AS lifted its position in Waters by 9.4% during the 1st quarter. DNB Asset Management AS now owns 11,991 shares of the medical instruments supplier’s stock worth $3,722,000 after buying an additional 1,032 shares in the last quarter. Finally, Diversified Trust Co lifted its position in Waters by 14.1% during the 1st quarter. Diversified Trust Co now owns 5,190 shares of the medical instruments supplier’s stock worth $1,611,000 after buying an additional 641 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.
WAT opened at $293.93 on Wednesday. The company has a fifty day moving average price of $319.52 and a two-hundred day moving average price of $336.87. The company has a debt-to-equity ratio of 4.12, a quick ratio of 1.87 and a current ratio of 2.39. Waters has a 52 week low of $292.51 and a 52 week high of $428.22. The firm has a market capitalization of $17.94 billion, a PE ratio of 26.29, a P/E/G ratio of 3.11 and a beta of 0.89.
About Waters (Get Rating)
Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services.
- Get a free copy of the StockNews.com research report on Waters (WAT)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- Tilray Stock Has Better Days Ahead
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.